SWOT Analysis for Cue Biopharma Inc

Companies with 10% increase in share price over three months, with rising net profit growth
Relative Outperformance versus Industry over 1 Month
Relative Outperformance versus Industry over the Quarter (3 Months)
Annual Profit Growth higher than Sector Profit Growth
PEG lower than Industry PEG
Relative Outperformance versus Industry over 1 Month
Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years
Annual Net Profits improving for last 2 years
Stock with Low PE (PE < = 10)
Volume Shockers
Stocks Outperforming their Industry Price Change in the Quarter

Bearish Stocks - Stocks with Medium to Low Trendlyne Momentum Score
Stocks with Expensive Valuations according to the Trendlyne Valuation Score
Inefficient use of shareholder funds - ROE declining in the last 2 years
Inefficient use of assets to generate profits - ROA declining in the last 2 years
Highest fall from 52 Week High
Low Piotroski Score : Companies with weak financials
Declining Net Cash Flow : Companies not able to generate net cash
Book Value Per Share deteriorating for last 2 years

Mutual Funds Increased Shareholding in Past Month
Institutions increasing their shareholding
Mutual Funds Increased Shareholding over the Past Two Months
MFs increased their shareholding last quarter
Mf buying for 2 months

Cue Biopharma Inc SWOT Analysis: Strengths, Weakness, Opportunity, and Threats